Back to Search

DAVID BROWN, P.T.

P.T.

Physical Therapist

NPI: 1437200110IndividualAccepts Medicare

Specialties, Licenses & Credentials

Physical TherapistPrimary

Physical Therapist

Code: 225100000X

16655(MD)

CMS Specialties

PrimaryPHYSICAL THERAPIST IN PRIVATE PRACTICE

Education

OTHER

Class of 1989

Clinical Trials (1)

1
Linked Trials
0
Recruiting
1
With Results

Study for Recalcitrant Age Related Macular Degeneration

NCT01543568COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR

Research & Publications (15)

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
PMID 24518078·Br J Ophthalmol·2014
4-observational
Aflibercept (eylea) for age-related macular degeneration.
PMID 22354219·Med Lett Drugs Ther·2012
6-review
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.
PMID 22300011·Expert Opin Pharmacother·2012
6-review
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
PMID 21526923·N Engl J Med·2011
4-observational
Fundus autofluorescence and visual acuity in central serous chorioretinopathy.
PMID 21055816·Ophthalmology·2011
8-other
Vascular endothelial growth factor Trap-Eye for diabetic macular oedema.
PMID 19174397·Br J Ophthalmol·2009
8-other
Predicted biological activity of intravitreal VEGF Trap.
PMID 18356264·Br J Ophthalmol·2008
4-observational
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
PMID 17386270·Am J Ophthalmol·2007
3-trial
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
PMID 17021319·N Engl J Med·2006
4-observational
Ranibizumab for neovascular age-related macular degeneration.
PMID 17021318·N Engl J Med·2006
3-trial
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
PMID 16458968·Ophthalmology·2006
5-case
Pegaptanib for neovascular age-related macular degeneration.
PMID 15625332·N Engl J Med·2004
3-trial
Cystoid macular degeneration in chronic central serous chorioretinopathy.
PMID 12652224·Retina·2003
8-other
VEGF-Trap: a VEGF blocker with potent antitumor effects.
PMID 12177445·Proc Natl Acad Sci U S A·2002
7-preclinical
Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
PMID 11927845·Retina·2002
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3179 BRAVERTON ST, SUITE 201
EDGEWATER, MD 21037

Location

Practice Location

3179 BRAVERTON ST, EDGEWATER, MD
(410) 956-4308

Quick Facts

NPI
1437200110
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
37
Clinical Trials
1
Publications
15

Are you this provider?

Claim Your Profile